Fabrizio Citarella
Overview
Explore the profile of Fabrizio Citarella including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
677
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rakaee M, Tafavvoghi M, Ricciuti B, Alessi J, Cortellini A, Citarella F, et al.
JAMA Oncol
. 2024 Dec;
11(2):109-118.
PMID: 39724105
Importance: Only a small fraction of patients with advanced non-small cell lung cancer (NSCLC) respond to immune checkpoint inhibitor (ICI) treatment. For optimal personalized NSCLC care, it is imperative to...
2.
Cortellini A, Citarella F, Vendittelli A, Fiorenti M, Mingo E, Cascetta P, et al.
J Chemother
. 2024 Aug;
:1-9.
PMID: 39104255
Guidelines historically recommended mono-chemotherapy for the 1 line treatment of elderly patients with non-small cell lung cancer (NSCLC) and poor performance status (PS). Nowadays, there is no clear indication whether...
3.
Citarella F, Takada K, Cascetta P, Crucitti P, Petti R, Vincenzi B, et al.
J Transl Med
. 2024 Jul;
22(1):714.
PMID: 39085889
Compared to other malignancies, few studies have investigated the role of family history of cancer (FHC) in patients with lung cancer, yielding largely heterogeneous results. We performed a systematic literature...
4.
Leonetti A, Perrone F, Puntoni M, Maglietta G, Bordi P, Bria E, et al.
Eur J Cancer
. 2024 Mar;
202:114006.
PMID: 38489861
Purpose: The aim of this multi-center, retrospective/prospective cohort observational study was to evaluate outcomes in routine clinical practice of first-line chemo-immunotherapy with cis/carboplatin, pemetrexed and pembrolizumab in patients with advanced...
5.
Passiglia F, Reale M, Lo Russo G, Pasello G, Minuti G, Bulotta A, et al.
Lung Cancer
. 2023 Dec;
187:107444.
PMID: 38157806
Background: Sotorasib showed a significant improvement of progression free survival (PFS), safety and quality of life over docetaxel in patients with KRASp.G12C-mutated advanced non-small-cell lung cancer (NSCLC) within the CodeBreak-200...
6.
Cantini L, Paoloni F, Pecci F, Spagnolo F, Genova C, Tanda E, et al.
J Natl Cancer Inst
. 2023 Apr;
115(7):796-804.
PMID: 37042716
Background: Real-life spectrum and survival implications of immune-related adverse events (irAEs) in patients treated with extended interval dosing (ED) immune checkpoint inhibitors (ICIs) are unknown. Methods: Characteristics of 812 consecutive...
7.
Salvatore L, Bensi M, Vivolo R, Zurlo I, DellAquila E, Grande R, et al.
Front Oncol
. 2023 Mar;
13:1125013.
PMID: 36895480
Background: Right- (R) and left-sided (L) metastatic colorectal cancer (mCRC) exhibit different clinical and molecular features. Several retrospective analyses showed that survival benefit of anti-EGFR-based therapy is limited to RAS/BRAF...
8.
Russano M, La Cava G, Cortellini A, Citarella F, Galletti A, Di Fazio G, et al.
Curr Oncol
. 2023 Feb;
30(2):2366-2387.
PMID: 36826142
Immunotherapy has revolutionized the treatment paradigm of non-small cell lung cancer and improved patients' prognosis. Immune checkpoint inhibitors have quickly become standard frontline treatment for metastatic non-oncogene addicted disease, either...
9.
Aldea M, Marinello A, Duruisseaux M, Zrafi W, Conci N, Massa G, et al.
J Thorac Oncol
. 2023 Jan;
18(5):576-586.
PMID: 36646211
Introduction: Nearly 1% to 2% of NSCLCs harbor RET fusions. Characterization of this rare population is still incomplete. Methods: This retrospective multicenter study included patients with any-stage RET positive (RET+)...
10.
Pantano F, Zalfa F, Iuliani M, Simonetti S, Manca P, Napolitano A, et al.
Cancers (Basel)
. 2022 May;
14(10).
PMID: 35626040
Immune checkpoint inhibitors (ICIs) are largely used in the treatment of patients with advanced non-small-cell lung cancer (NSCLC). Novel biomarkers that provide biological information that could be useful for clinical...